Objective: To report long-term outcome of patients undergoing prosthetic 8-mm H-graft portacaval shunts (HGPCS) or TIPS and to compare actual with predicted survival data. Methods: A randomized trial comparing TIPS to HGPCS for bleeding varices began in 1993. Predicted survival was determined using MELD (Model for End-stage Liver Disease). Results: Patients undergoing TIPS (N ϭ 66) or HGPCS (N ϭ 66) were very similar by Child's class and MELD scores and predicted survival. After TIPS (P ϭ 0.01) and HGPCS (P ϭ 0.001), actual survival was superior to predicted survival. Through 24 months, actual survival after HGPCS was superior to actual survival after TIPS (P ϭ 0.04). Compared with TIPS, survival was superior after HGPCS for patients of Child's class A and B (P ϭ 0.07) and with MELD scores less than 13 (P ϭ 0.04) with follow-up at 5 to 10 years. Shunt failure was less following HGPCS (P Ͻ 0.01). Conclusions: Predicted survival data for patients undergoing TIPS or HGPCS confirms an unbiased randomization. Actual survival following TIPS or HGPCS was superior to predicted survival. Shunt failure favored HGPCS, as did survival after shunting, particularly for the first few years after shunting and for patients of Child's class A or B or with MELD scores less than 13. This trial irrefutably establishes a role for surgical shunting, particularly HGPCS. (Ann Surg 2005;241: 238 -246) From the
N onsurgeons increasingly control the care of patients experiencing variceal bleeding due to cirrhosis and portal hypertension. This has promoted the application of nonsurgical therapies, specifically the transjugular intrahepatic portasystemic stent shunt (TIPS). As a consequence, surgeons-in-practice are generally not involved in the care of patients bleeding from varices due to cirrhosis and portal hypertension, which is a notable departure from the past. As well, surgeons-in-training see fewer patients with variceal bleeding than in days past, and may never participate in the care of a patient with bleeding varices. Thereby, most surgeons believe that portasystemic shunting is not in their therapeutic armamentarium, further promoting the involvement of nonsurgeons and the application of TIPS.
While TIPS was initially proposed to be an ideal vehicle to serve as a "bridge" to transplantation, rates of rebleeding after TIPS are thought by its proponents to be acceptably low encouraging its application with ever broadening indications. Proponents of TIPS note that techniques of TIPS placement and algorithms of patient care after TIPS are quite standard, allowing for relatively uniform results. As well, they believe that TIPS construction can be undertaken with widely available "special" interventional radiology skills; thus, TIPS has applicability across the United States and the world. Thus, as a consequence, TIPS has generally become globally recognized and accepted as a first-line therapy for the control bleeding varices due to cirrhosis and portal hypertension.
Supporters of surgical shunting are few. Interest in portal hypertension is waning among surgeons. Transplantation is recognized as the only definitive approach to complicated cirrhosis and portal hypertension, and TIPS seems by most to fit a perfect role in bridging patients to transplantation as if all patients needed transplants. For patients with bleeding varices due to cirrhosis and portal hypertension, considerations for definitive therapy other than TIPS and/or transplantation are decreasingly, if ever, considered, further decreasing the application of surgical shunting.
It is fascinating that TIPS has achieved its status in the treatment of complicated portal hypertension without trials favorably comparing it with surgical shunting. Efficacy of TIPS has been incompletely documented, always without a comparative yardstick, and complications of TIPS, such as stenosis and occlusion, are noted but not considered to be significant hindrances to the application of TIPS. Hepatic dysfunction after TIPS seems to be uniformly attributed to progression of underlying liver disease without considering that it might be a consequence of excessive portal diversion by TIPS.
We began a prospective randomized clinical trial in 1993 to compare the relative efficacy and safety of TIPS versus surgical shunting when treating patients with cirrhosis, portal hypertension, and variceal hemorrhage. The purpose of this report is to detail the follow-up of patients in this protocol, which now extends beyond 10 years for some patients. Specifically, this report was undertaken to evaluate the fairness of the randomization utilizing a model designed to predict survival after TIPS (Model for End-stage Liver Disease, MELD), 1-3 to compare predicted (MELD) with actual survival data, and to document and compare long-term shunt failure and survival of patients undergoing either TIPS or 8 mm H-graft portacaval shunts (HGPCSs). Our hypotheses in undertaking this report were that the randomization of patients was unbiased, that patients undergoing shunting in our trial did as well as predicted by MELD, and that patients undergoing HGPCSs would have superior long-term survival relative to patients undergoing TIPS.
PATIENTS AND METHODS
In 1993, after institutional review board approval, patients with cirrhosis, portal hypertension, and variceal hemorrhage began to be prospectively accrued into a randomized trial comparing TIPS to 8-mm prosthetic HGPCSs. All had experienced bleeding from varices or portal gastropathy, and all had failed or were not amenable to endoscopic therapy. Shunting was always undertaken as definitive therapy, never as a bridge to transplantation. Given that, subsequent transplantation was only undertaken to avoid imminent death due to progressive hepatic dysfunction.
The severity of cirrhosis was staged by assigning a Child's class to each patient. Before being randomized to either shunt, all patients underwent color-flow Doppler ultrasound imaging to document the quality and direction of portal blood flow. If there were questions regarding portal vein patency, mesenteric angiography with venous phase study was undertaken. After informed consent was obtained, patients were randomized to undergo TIPS or 8-mm prosthetic HGPCSs. Patients were randomized, using a computerized randomization program, in pairs to allow for sequential analysis by pair differences. Patients were not considered for this trial if their portal veins were thrombosed, if they were of profound ill health, or if hepatic dysfunction was thought to preclude even short-term survival after shunting.
Our grading of encephalopathy and ascites has been previously described. 4 Circumstances of shunting were defined as elective (shunting scheduled for convenience in a stable patient), urgent (shunting undertaken within 24 hours of encountering the patient), or emergency (shunting undertaken as soon as possible, certainly within 8 hours encountering the patient).
Our technique of TIPS placement has been described 4 : 10 mm 68 mm Schneider Wall stents (Pfizer, Inc, New York, NY) were used. The stents were dilated to 8 to 10 mm or until a 5-to 10-mm Hg gradient between the portal vein and hepatic vein or inferior vena cava was reached.
As well, our technique of HGPCS construction has been described in detail. 5 The shunts were constructed utilizing 8-mm-diameter externally ring-reinforced PTFE with bevels at each end oriented 90°to each other to accommodate for the orientation of the portal vein to the inferior vena cava. The graft was never longer than 3.0 cm from toe to toe and 1.5 cm from heel to heel. With shunting, several changes were sought: a decrease of the portal pressure of more than 10 mm Hg, a decrease of the portal vein-inferior vena cava pressure gradient of 10 mm Hg or more, and a postshunt portal vein-inferior vena cava pressure gradient of less than 10 mm Hg. A thrill along the inferior vena cava just cephalad to the cava-graft anastomosis helped confirm shunt patency. Retroperitoneal collaterals were not aggressively ligated.
Prior to discharge from the hospital, transvenous cannulation of the shunts confirmed patency. Portal vein-inferior vena cava pressure gradients were determined. Direction and quality of portal flow was determined. Color-flow Doppler ultrasound studies of the TIPS shunts were obtained to establish baseline flow measurements. Shunt stenosis or thrombosis was documented and corrected, if present.
For long-term follow-up after TIPS, color-flow Doppler ultrasound evaluation of the shunts was undertaken at 6 weeks, 12 weeks, and 6 months. Thereafter, color-flow Doppler ultrasound evaluation was undertaken every 6 months. Studies compatible with stent stenosis (reduced or increased flow velocities of 40 cm/s relative to baseline) led to transjugular shunt assessment with interventions as necessary.
Color-flow Doppler ultrasound was not used to follow patients after HGPCSs, as the orientation of the shunts to the "window" of the liver does not allow for assessment of shunt flow or patency. Therefore, after HGPCS, patients were followed only with transfemoral cannulation of the shunt, which was undertaken at 1, 3, 5, 7, and 10 years.
In undertaking this trial, shunt failure was prospectively defined as an inability to complete shunting or place the shunt, irreversible shunt occlusion, major variceal rehemorrhage, liver failure requiring transplantation in lieu of death, or death. Major variceal rehemorrhage was defined as gastrointestinal blood loss documented by endoscopy to be emanating from varices or portal gastropathy requiring hospitalization and blood transfusions.
Preshunt MELD scores and predicted survival after shunting have been determined, with considerations to the cause of cirrhosis. [1] [2] [3] Data, when appropriate, are expressed as median or mean Ϯ SD. Mean and median survival data were derived from survival curve analysis. Data were stored on a spreadsheet registry (Microsoft Excel, Redman, WA). Statistical comparisons were undertaken using True Epistat (Epistat Services, Richardson, TX). When 2 testing was used, methods for prospective trials were used. Statistical significance was assigned at 95% probability.
Follow-up after shunting ranges from 5. 
RESULTS

Patient Demographics
A total of 132 patients (92 males and 40 females) were randomly assigned to undergo TIPS or 8-mm prosthetic HGPCS (Table 1) . Demographically, the patients randomized to each shunt were similar ( Table 1) . "Other" causes of cirrhosis prior to TIPS were autoimmune cirrhosis. "Other" causes of cirrhosis prior to HGPCS were autoimmune cirrhosis and methotrexate induced cirrhosis. The majority of pa-tients undergoing either shunt were of Child's class B or C. The median and mean MELD scores were identical for patients undergoing TIPS versus H-graft shunts (Table 1) , and they were parametrically and similarly distributed among patients undergoing either shunt ( Fig. 1 ). Representative preoperative laboratory values are noted in Table 2 ; no apparent differences are statistically significant.
For patients undergoing TIPS, indications for shunting were bleeding esophageal varices in 45%, bleeding gastric varices in 12%, and bleeding esophageal and gastric varices in 43%. Similarly, of patients undergoing HGPCS, 58% were bleeding from esophageal varices, 10% from gastric varices or portal gastropathy, and 32% were bleeding from both esophageal and gastric varices. TIPS was undertaken electively in 78%, urgently in 10%, and as an emergency in 12%. HGPCSs were placed electively in 74%, urgently in 14%, and as emergencies in 12%.
Pressure Measurements
Portal pressures and portal vein-inferior vena cava pressure gradients decreased significantly after TIPS or HGPCS (Table 3 ). Both shunts resulted in partial portal decompression. Decompression was significantly more pronounced following HGPCS.
Inability to Shunt
TIPS were unable to be completed in 2 patients because of the inability to puncture the fibrotic livers. One died of complications related to varices, cirrhosis, and portal hypertension within 2 weeks of the attempted shunting, but not as a direct consequence of the attempted shunting. The other was lost to follow-up after refusing further care. These patients were censored from survival analysis.
Perioperative and Periprocedural Mortality
Ten patients (15%) died within 30 days after TIPS. Of these, 70% were of Child's class C and 30% were of Child's After HGPCS, early death was related to liver failure in 92%. One (8%) death on the day of shunting was from respiratory compromise due to self-extubation and an inability to subsequently secure an airway.
Shunt Stenosis and Thrombosis
After TIPS, shunt stenosis and thrombosis occurred in significantly more patients (P Ͻ 0.001, Fisher exact test) with greater frequency (P Ͻ 0.001, Student t test) than after HGPCS (Table 4 ). After TIPS, 32 patients underwent 66 interventions to maintain shunt patency. A notable number of patients underwent 3, 4, 5, and 6 revisions. Conversely, after HGPCS, 7 patients underwent 8 interventions to maintain shunt patency and/or function. One required operative inter-vention 5 days after shunting to revise an occluded shunt. Six patients were noted to have relatively high pressure gradients at the time of routine transfemoral study and successfully underwent balloon angioplasty.
Irreversible shunt occlusion (ie, terminal shunt occlusion) occurred in 5 patients after TIPS and in 3 patients after HGPCS (P ϭ not significant). After TIPS, irreversible shunt occlusion presented as major variceal rehemorrhage. After HGPCS, irreversible shunt occlusion was detected through transfemoral evaluation of the shunts during scheduled studies, which were part of routine follow-up.
Variceal Hemorrhage
After TIPS, major variceal rehemorrhage presaged documentation of shunt stenosis or thrombosis for 20 patients. For 2 patients, major variceal rehemorrhage occurred within 30 days of shunting, and for 18 patients after TIPS major variceal rehemorrhage occurred more than 30 days after shunting. Following HGPCSs, 5 patients experienced upper gastrointestinal bleeding, all because of alcoholic gastritis. None of the patients experiencing bleeding following H-graft portacaval shunting had stenotic or thrombosed portacaval shunts.
Postoperative Ascites and Encephalopathy
Ascites persisted more than 30 days after TIPS or HGPCS in 60% of those with preoperative ascites. Ultimately, ascites was noted at late follow-up in 40% of patients after TIPS and in 28% of patients after HGPCS (P ϭ not 
Liver Transplantation
Hepatic transplantation was undertaken to avoid death due to hepatic failure for 6 (9%) patients following TIPS and for 1 (1.5%) following HGPCS. Previous shunting did not seem to impact transplantation. Preshunt Child's classes, MELD scores, and the timing of transplantation after shunting are noted in Table 5 .
Mortality
Ninety 7 (73%) patients have died, 48 following TIPS and 49 following HGPCS. The causes of death are generally known and are generally due to hepatic failure ( Table 6 ). The median (SD) time to death following TIPS was 29 months (41 Ϯ 39.4 months) compared with 55 months (53 Ϯ 40.1 months) after H-graft shunts.
Predicted survival after TIPS and after H-graft shunting was determined using MELD (Table 7) . Predicted survival after the shunts was nearly identical (Table 7) . Actual survival after either of the shunts was significantly better than predicted (P Ͻ 0.001, Mantel Henzel 2 ) ( Table 7) . Using survival data at 3, 6, 12, and 24 months after shunting, actual survival after H-graft shunts was significantly better than after TIPS (P Ͻ 0.001, Mantel Henzel 2 ).
By regression analysis, MELD scores predicted survival after TIPS (r ϭ Ϫ0.34, P Ͻ 0.005) and after H-graft shunts (r ϭ Ϫ0.49, P ϭ 0.0003). The regression curves were not nonparallel (P ϭ 0.565). For patients with MELD scores less than 13, survival was significantly superior after H-graft shunts (N ϭ 30) than after TIPS (N ϭ 30) (P ϭ 0.04, Wilcoxon Test).
For patients of Child's class A, survival was longer after H-graft shunting than after TIPS (P ϭ 0.01, Wilcoxon Test) ( Fig. 2B ). For patients of Child's class B, survival was longer after H-graft shunting than after TIPS (P ϭ 0.02, Wilcoxon Test) ( Fig. 2C ). For patients of Child's class A or B grouped together, survival was longer after H-graft shunting than after TIPS (P ϭ 0.004, Wilcoxon Test). For patients of Child's class C, survival was not longer after H-graft shunting than after TIPS (P ϭ 0.31, Wilcoxon Test) ( Fig.  2D ). For all patients, survival was not longer after H-graft shunting than after TIPS (P ϭ 0.21, Wilcoxon Test) ( Fig.  2A) . Summary information is contained in Table 8 .
Failure After Shunting
Failure after shunting (as prospectively defined) has occurred in the majority of patients with follow-up as long as more than 10 years (Table 9 ). Overall, there were 86 of occurrences of failure after TIPS occurring in 54 patients compared with 53 occurrences of failure in 49 patients following H-graft shunts. These failures are predominantly a result of death. Patients undergoing TIPS were more likely to fail because of major variceal hemorrhage (P Ͻ 0.01, Fisher exact test).
After H-graft shunts, patients had a significantly longer time before failure (Table 10 ) than patients undergoing TIPS. Time to failure after each of the shunts was also compared by survival curve analysis and found to be significantly superior after the 8-mm prosthetic HGPCSs (P ϭ 0.048, Wilcoxon Test). This is particularly true for patients of Child's class A or B (Table 10) . By regression analysis, MELD scores predicted failure after TIPS (r ϭ 0.424, P ϭ 0.004) and after H-graft shunts (r ϭ 0.286, P ϭ 0.02). The regression curves were not nonparallel (P ϭ 0.525). For patients with MELD scores less than 14, time to shunt failure was significantly superior after H-graft shunts (N ϭ 36) than after TIPS (N ϭ 36) (P Ͻ 0.03, Wilcoxon Test).
DISCUSSION
The role of TIPS continues to evolve. Interested providers monitor new reports that hopefully clarify the results with TIPS. Unfortunately, few reports give a full picture of outcomes with TIPS, and fewer yet have include a "yardstick" with which to compare TIPS. This prospective randomized clinical trial compares TIPS to an operatively constructed, or surgical, shunt, the small-diameter prosthetic HGPCS. Follow-up in this trial is beyond 10 years in some patients, with a median follow-up at 8 years. This trial irrefutably establishes a role for surgical shunting.
A significant number of patients (more than 100) were randomized in this trial. Most patients were middle-aged white males with alcoholic liver disease and advanced cirrhosis that had experienced bleeding from esophageal varices and failed endoscopic therapy. Most presented with ascites. A minority, but notable number, presented with encephalopathy, which was an ominous predictor of postshunt death. Shunting was usually undertaken electively. Median and mean preshunt MELD scores portend poor prognoses, suggesting a survival of 1 year, on average. 2 The patients undergoing prosthetic HGPCS were nearly identical to those undergoing TIPS by descriptive comparison, by Child's classification, by MELD scores, and by predicted survival. By all measures, the randomization involved in this trial was unbiased and resulted in 2 nearly identical groups of patients that allow for meaningful comparisons of these 2 methods of partial portal decompression. Duration of follow-up of patients undergoing either shunt is significant and very similar, especially given survival differences favoring the H-graft shunt.
Both shunts provided partial portal decompression. The decompression achieved by each shunt is consistent with other series. 6 -8 Each shunt significantly decreased portal pressures and portal vein-inferior vena cava pressure gradients. The decompression by TIPS would be thought by some to be excessive for optimal outcomes. 9 Nonetheless, decompression was greater with HGPCS, although portal pressures and portal vein-inferior vena cava pressure gradients were not reduced beyond normal and physiologic, on average. TIPS could not be placed in 2 patients. These patients were relatively early in this trial. Being unable to place functioning TIPS in 2 (3%) patients of 66 is well within any usual range. 7,9 -12 The periprocedural mortality of this trial has been discussed previously. 4 Nearly 1 of 5 patients died within 30 days of shunting, nearly always because of hepatic decompensation. As is no surprise, more than three fourths were of Child's class C, reflecting poor hepatic reserve.
Shunt stenosis and thrombosis were particularly an issue after TIPS. This isn't a new finding. 6, 7, [12] [13] [14] [15] Half the patients undergoing TIPS had significant shunt/stent stenosis occur, often leading to clinically significant variceal hemorrhage. As in other series, the shunt/stent could usually be salvaged with radiologic intervention. Many patients required multiple interventions to sustain shunt patency. Conversely, it is very uncommon to lose prosthetic H-graft shunt patency after shunting, especially early after shunting. Once discharged with a patent shunt, it is very unlikely that prosthetic H-graft shunt patency will be lost. Routine transvenous shunt studies undertaken infrequently, at intervals of 1, 3, 5, 7, and 10 years, after shunting detected high gradients in only a handful of patients, which, for each patient, was easily corrected with balloon angioplasty. Presumably, neointimal hyperplasia was the offending process in these shunts.
As would be expected, variceal bleeding was often a consequence of shunt stenosis or thrombosis. 7 A significant number of patients rebled from varices after TIPS, as opposed to H-graft shunts. Alcoholic gastritis caused gastrointestinal bleeding in a small number of patients after H-graft shunts. Even if these patients are considered to have experienced variceal bleeding, bleeding from varices was still more frequent after TIPS. A study comparing TIPS to distal spleno- renal shunts also reported more frequent recurrences of variceal bleeding after TIPS (26% vs. 6%). 6 Despite our vigilance with TIPS follow-up and assessment, a small but notable number of patients experienced irreversible TIPS shunt occlusion. As well, this infrequently occurred after H-graft shunts. Usually, TIPS stenosis or thrombosis was corrected by interventional radiology and the shunt salvaged. Vigilance with follow-up is necessary, particularly since variceal rehemorrhage can be the first sign of TIPS shunt malfunction. Major variceal rehemorrhage after TIPS is no illusion. It happens too frequently and can be fatal, as it was in a number of patients in this trial.
There was a multitude of causes of death in this trial. Undertaking liver transplantation to avoid death due to progressive hepatic dysfunction results in understating death due to liver failure. Even so, liver failure was the most frequent cause of death, consistent with other reports. 15, 16 Death was due to unknown causes in a significant number of patients. Some of the patients dying of unknown causes wasted away with total body failure or "old age." Hepatic decompensation certainly played a major role in these deaths. These deaths often occurred under the watchful eyes of family doctors or family members, often "up North," with quick disposal of the body making it impossible for us to learn more about the patients' deaths. Cancer deaths in this trial seem unrelated to shunting.
Others have found MELD to accurately predict survival after TIPS. [17] [18] [19] Herein, actual survival for patients undergoing TIPS or H-graft shunts was significantly better than predicted with MELD. Actual survival after H-graft shunts was significantly better than after TIPS using the same time points used in predicting survival with MELD. Through MELD, we know that superior survival after H-graft shunts is not due to poor outcomes associated with TIPS in this trial, but rather, because of inherent differences between the shunts, probably related to postshunt blood flow. 20, 21 On a broader scope, by survival curve analysis, actual survival after H-graft shunts was better than after TIPS, but only for patients of Child's class A and/or B or with MELD scores less than 13. Patients of Child's class C had similar survival after TIPS or H-graft shunts, although survival for patients of Child's class C after TIPS seems unexpectedly strong. Previously, we have studied patients of Child's class C in detail and found that, although they don't live longer after H-graft shunts than TIPS, they require fewer resources after H-graft shunts because of fewer problems with shunt stenosis and variceal rehemorrhage, despite vigilant TIPS follow-up. 22 With a trial like this, with patients like this, who have problems like these, the survival curves of patients undergoing TIPS or H-graft shunts will ultimately converge. Survival differences seen in this trial, as no surprise, are most striking in the early and intermediate years of this trial. For patients of Child's class A and/or B or with MELD scores less than 13, actual survival after H-graft shunts was better than after TIPS by survival curve analysis.
Failure after shunting mimics death after shunting. With the long follow-up of this trial, the majority of patients have failed after shunting, usually because they died. Shunt failure was more common after TIPS than after H-graft shunting, generally because of increased variceal bleeding after TIPS. Variceal bleeding after TIPS is relatively common, 6, 15 usually because of shunt stenosis or thrombosis. 7 In a meta-analysis of randomized clinical trials, the average rate of recurrent bleeding after TIPS was 20% 15 with generally short follow-up. Shunt failure occurred significantly later after H-graft shunts than after TIPS. This is particularly true for patients with MELD scores of less than 14. In other words, for patients with MELD scores of less than 14, significantly longer time was seen between shunting and shunt failure after H-graft shunts than after TIPS.
This trial begs the question, "Who should undergo which shunt?" For patients of Child's class A or B or with MELD scores less than 14, small-diameter prosthetic HGPCSs should be applied. For patients with MELD scores greater than or equal to 14 in whom hepatic transplantation is not imminent, HGPCSs can palliate portal hypertension with relative con- 22 For patients with MELD scores greater than or equal to 14, TIPS should be a consideration and should be applied if hepatic transplantation is imminent, ie, aggressively pursued to be undertaken within the next few months. If hepatic transplantation is not imminent, HGPCSs should be used if chances of later transplantation or vigilant care of the TIPS will be unlikely because of socioeconomic issues or a lack of ready access to health care. TIPS seems well applied to patients in need of portal decompression who are unacceptable operative candidates, ie, patients with histories of multiple right upper quadrant abdominal operations, super obesity, or severe cardiopulmonary disease, especially mitral regurgitation complicating aortic stenosis.
